Concordia International Corp. has revealed the names of six of its products that are the subject of additional investigations opened in October last year by the UK Competition and Markets Authority as part of the CMA’s ongoing probe into anticompetitive behavior in the pharmaceutical market.
The products are: the hyperthyroidism drug carbimazole, the muscle relaxant dicycloverine, the analgesic nefopam, the antibiotic nitrofurantoin, prochlorperazine for schizophrenia,...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?